anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Swimming training for asthma in children and adolescents aged 18 years and under
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Adolescent 13-18 years 4. Asthma
Provide patient population that should be included in the study
Inhaled corticosteroids for subacute cough in children
1. Child, Preschool 2-5 years 2. Subacute Cough 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Lung protective ventilation strategy for the acute respiratory distress syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Intubation 7. Mechanical ventilation 8. Aged 65-79 years 9. Acute Lung Injury 10. Acute Respiratory Distress Syndrome 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Intubation 5. Mechanical ventilation 6. Acute Respiratory Distress Syndrome 7. Acute Lung Injury 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Adolescent 13-18 years 5. Asthma
Provide patient population that should be included in the study
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Psychosocial interventions for reducing antipsychotic medication in care home residents
1. Living In Residential Institution
Provide patient population that should be included in the study
Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings
1. Aged 80 and over 80+ years 2. Institutionalized 3. Aged 65-79 years
Provide patient population that should be included in the study
Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive rehabilitation for people with mild to moderate dementia
1. Dementia
Provide patient population that should be included in the study
Personally tailored activities for improving psychosocial outcomes for people with dementia in long‐term care
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Living In Residential Institution 5. Dementia
Provide patient population that should be included in the study
Cognitive stimulation to improve cognitive functioning in people with dementia
1. Dementia
Provide patient population that should be included in the study
Non‐pharmacological interventions for sleep disturbances in people with dementia
1. Dementia
Provide patient population that should be included in the study
Pharmacological interventions for the treatment of disordered and problem gambling
1. Compulsive Gambling
Provide patient population that should be included in the study
Interventions for preventing and reducing the use of physical restraints of older people in general hospital settings
1. Aged 80 and over 80+ years 2. Hospitalization 3. Aged 65-79 years
Provide patient population that should be included in the study
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
1. Small Vessel Cerebrovascular Disease
Provide patient population that should be included in the study
Algorithm‐based pain management for people with dementia in nursing homes
1. Cognitive impairment 2. Dementia
Provide patient population that should be included in the study
Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Trauma 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Aged 65-79 years
Provide patient population that should be included in the study
Multi‐domain interventions for the prevention of dementia and cognitive decline
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years
Provide patient population that should be included in the study
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Bipolar Disorder 4. Young Adult 19-24 years 5. Depression 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Lamotrigine in the maintenance treatment of bipolar disorder
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Bipolar Disorder 4. Young Adult 19-24 years 5. Adolescent 13-18 years 6. Bipolar Disorder In Remission
Provide patient population that should be included in the study
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Depression 6. Unipolar disorder 7. Aged 65-79 years
Provide patient population that should be included in the study
Enteral tube feeding for people with severe dementia
1. Not reported 2. Dementia
Provide patient population that should be included in the study
Magnetic seizure therapy for treatment‐resistant depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Treatment-resistant depression 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Hypertensive disorder
Provide patient population that should be included in the study
Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety disorders in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Antidepressants 4. Young Adult 19-24 years 5. Depression 6. Anxiety Disorder 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis
1. Vascular Dementia 2. Not reported
Provide patient population that should be included in the study
Antidepressant treatment for postnatal depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Postpartum Depression 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Dementia
Provide patient population that should be included in the study
Pharmacological interventions for self‐harm in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Self-harm 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Remotely delivered information, training and support for informal caregivers of people with dementia
1. Caregiver 2. Dementia
Provide patient population that should be included in the study
Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings
1. Not reported 2. Mild Cognitive Impairment 3. Dementia
Provide patient population that should be included in the study
Behavioural activation therapy for depression in adults with non‐communicable diseases
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Critical Illness 5. Depression
Provide patient population that should be included in the study
Avatar Therapy for people with schizophrenia or related disorders
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Delusional Disorder 7. Aged 65-79 years
Provide patient population that should be included in the study
Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Normal Cognition 6. Mild Cognitive Impairment 7. Aged 65-79 years
Provide patient population that should be included in the study
Simulated presence therapy for dementia
1. Dementia
Provide patient population that should be included in the study
Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life
1. Normal Cognition 2. Elderly
Provide patient population that should be included in the study
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Parkinson's Disease 6. Mild Cognitive Impairment 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Dementia Due To Parkinson's Disease 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery
1. Aged 80 and over 80+ years 2. Hip Fracture 3. Aged 65-79 years 4. Dementia
Provide patient population that should be included in the study
Psychosocial interventions for people with both severe mental illness and substance misuse
1. Severe mental disorder 2. Substance Misuse Behavior
Provide patient population that should be included in the study
Couple and family therapies for post‐traumatic stress disorder (PTSD)
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Posttraumatic Stress Disorder
Provide patient population that should be included in the study
Present‐centered therapy (PCT) for post‐traumatic stress disorder (PTSD) in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Posttraumatic Stress Disorder 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Cerebrolysin for vascular dementia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vascular Dementia 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological interventions for the treatment of delirium in critically ill adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intensive Care 6. Aged 65-79 years
Provide patient population that should be included in the study
Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Trauma 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Mental disorder 6. Schizophrenia 7. Catatonia 8. Aged 65-79 years
Provide patient population that should be included in the study
Antidepressants plus benzodiazepines for adults with major depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Major depressive disorder 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies for preventing seasonal affective disorder
1. Adult 19-44 years 2. Seasonal Affective Disorder 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for preventing delirium in older people in institutional long‐term care
1. Aged 80 and over 80+ years 2. Elderly 3. Aged 65-79 years 4. Living In Residential Institution
Provide patient population that should be included in the study
Benzodiazepines versus placebo for panic disorder in adults
1. Panic Disorder Without Agoraphobia 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Panic Disorder With Agoraphobia 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive training for people with mild to moderate dementia
1. Dementia
Provide patient population that should be included in the study
Memantine for dementia
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Dementia
Provide patient population that should be included in the study
Electroconvulsive therapy for treatment‐resistant schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Treatment-resistant Schizophrenia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Second‐generation antidepressants for preventing seasonal affective disorder in adults
1. Adult 19-44 years 2. Seasonal Affective Disorder 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Computerised cognitive training for preventing dementia in people with mild cognitive impairment
1. Not reported 2. Mild Cognitive Impairment
Provide patient population that should be included in the study
Computerised cognitive training for maintaining cognitive function in cognitively healthy people in midlife
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Normal Cognition
Provide patient population that should be included in the study
Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for preventing intensive care unit delirium in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Valproate preparations for agitation in dementia
1. Agitated 2. Dementia
Provide patient population that should be included in the study
Antidepressants for treating depression in dementia
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Depression 4. Aged 65-79 years 5. Dementia
Provide patient population that should be included in the study
Environmental and behavioural modifications for improving food and fluid intake in people with dementia
1. Dementia
Provide patient population that should be included in the study
Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings
1. Aged 80 and over 80+ years 2. Delirium 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Donepezil for dementia due to Alzheimer's disease
1. Dementia Due To Alzheimer's Disease
Provide patient population that should be included in the study
Couple therapy for depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Heterosexual 4. Young Adult 19-24 years 5. Depression 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Processed electroencephalogram and evoked potential techniques for amelioration of postoperative delirium and cognitive dysfunction following non‐cardiac and non‐neurosurgical procedures in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. General Anesthesia 6. Aged 65-79 years
Provide patient population that should be included in the study
Antidepressants for preventing postnatal depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Mother Delivered 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Mental Disorder 6. Schizophrenia 7. Tardive dyskinesia 8. Aged 65-79 years
Provide patient population that should be included in the study
Antidepressants versus placebo for panic disorder in adults
1. Aged 80 and over 80+ years 2. Panic Disorder Without Agoraphobia 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Panic Disorder With Agoraphobia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Withdrawal versus continuation of long‐term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia
1. Aged 80 and over 80+ years 2. Aged 65-79 years 3. Dementia
Provide patient population that should be included in the study
Calcium channel blockers for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Mental Disorder 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Cholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Mental Disorder 6. Schizophrenia 7. Tardive dyskinesia 8. Aged 65-79 years
Provide patient population that should be included in the study
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Tardive dyskinesia 7. Schizophrenic Psychoses 8. Aged 65-79 years
Provide patient population that should be included in the study
Selective noradrenaline reuptake inhibitors for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Substance Misuse Behavior 4. Young Adult 19-24 years 5. Mental disorder 6. Substance Abuser 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Benzodiazepines for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Mental Disorder 6. Schizoaffective Disorder 7. Schizophrenia 8. Tardive dyskinesia 9. Aged 65-79 years
Provide patient population that should be included in the study
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Mental Disorder 6. Schizophrenia 7. Tardive dyskinesia 8. Aged 65-79 years
Provide patient population that should be included in the study
Anticholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Aggressive Behavior 6. Young Adult 19-24 years 7. Agitated 8. Aged 65-79 years
Provide patient population that should be included in the study
Benzodiazepines for psychosis‐induced aggression or agitation
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Aggressive Behavior 6. Young Adult 19-24 years 7. Agitated 8. Aged 65-79 years
Provide patient population that should be included in the study
Zuclopenthixol dihydrochloride for schizophrenia
1. Schizophrenia
Provide patient population that should be included in the study
Chlorpromazine versus penfluridol for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Aggressive Behavior 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Psychosis-induced agitation 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Vortioxetine for depression in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Major depressive disorder 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Antipsychotic combinations for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Communication skills training for mental health professionals working with people with severe mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Healthcare Professional 5. Young Adult 19-24 years 6. Mental state 7. Aged 65-79 years
Provide patient population that should be included in the study
Assistive technology for memory support in dementia
1. Dementia
Provide patient population that should be included in the study
Chlorpromazine versus clotiapine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Chlorpromazine versus metiapine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Treatment-resistant Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Compulsory community and involuntary outpatient treatment for people with severe mental disorders
1. Severe mental disorder
Provide patient population that should be included in the study
Risperidone versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Implementation of treatment guidelines for specialist mental health care
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Droperidol for psychosis‐induced aggression or agitation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Psychosis-induced agitation
Provide patient population that should be included in the study
Haloperidol for long‐term aggression in psychosis
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Haloperidol plus promethazine for psychosis‐induced aggression
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Psychosis-induced aggression
Provide patient population that should be included in the study
Valproate for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antihypertensive withdrawal for the prevention of cognitive decline
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. General Health Good 5. Young Adult 19-24 years 6. Mild Cognitive Impairment 7. Aged 65-79 years 8. Hypertensive disorder 9. Dementia
Provide patient population that should be included in the study
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults
1. Panic Disorder Without Agoraphobia 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Panic Disorder With Agoraphobia 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Bifeprunox versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies for children and adolescents exposed to trauma
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Trauma 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuation and maintenance treatments for depression in older people
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Depression 4. Aged 65-79 years
Provide patient population that should be included in the study
Topiramate for acute affective episodes in bipolar disorder in adults
1. Adult 19-44 years 2. Bipolar Affective Disorder, Current Episode Mixed 3. Middle Aged 45-64 years 4. Bipolar Disorder 5. Bipolar Affective Disorder, Current Episode Depression 6. Young Adult 19-24 years 7. Bipolar Affective Disorder, Current Episode Manic 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive behavioural therapy (CBT), third‐wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Young Adult 19-24 years 4. Depression 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Mental disorder 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological interventions for clozapine‐induced sinus tachycardia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Clozapine 8. Aged 65-79 years 9. Sinus Tachycardia
Provide patient population that should be included in the study
Psychosocial interventions for self‐harm in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Self-harm 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Chlorpromazine versus reserpine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta‐analysis
1. Panic Disorder Without Agoraphobia 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Panic Disorder With Agoraphobia 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Psychological therapies for post‐traumatic stress disorder and comorbid substance use disorder
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Psychoactive Substance Abuse 5. Posttraumatic Stress Disorder
Provide patient population that should be included in the study
Therapist‐supported Internet cognitive behavioural therapy for anxiety disorders in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Anxiety Disorder 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for preventing delirium in hospitalised non‐ICU patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiglucocorticoid and related treatments for psychosis
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Statins for the prevention of dementia
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Normal Cognition 4. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for self‐harm in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Self-harm 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Zuclopenthixol versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury
1. Traumatic Brain Injury
Provide patient population that should be included in the study
Asenapine versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Lithium for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Rivastigmine for Alzheimer's disease
1. Dementia Due To Alzheimer's Disease
Provide patient population that should be included in the study
Endoscopic third ventriculostomy (ETV) for idiopathic normal pressure hydrocephalus (iNPH)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-obstructive Hydrocephalus 6. Aged 65-79 years
Provide patient population that should be included in the study
Individual psychological therapy in the outpatient treatment of adults with anorexia nervosa
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Anorexia Nervosa 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological interventions for self‐harm in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Self-harm 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatments for delusional disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Delusional Disorder 6. Aged 65-79 years
Provide patient population that should be included in the study
Opioids for agitation in dementia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Agitated 6. Aged 65-79 years 7. Dementia
Provide patient population that should be included in the study
Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Anxiety Disorder 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychoeducation for siblings of people with severe mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Severe mental disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Sibling Support 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Aerobic exercise to improve cognitive function in older people without known cognitive impairment
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Normal Cognition 4. Aged 65-79 years
Provide patient population that should be included in the study
Latrepirdine for Alzheimer's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Dementia Due To Alzheimer's Disease
Provide patient population that should be included in the study
Debriefing interventions for the prevention of psychological trauma in women following childbirth
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Mother Delivered 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychoeducation (brief) for people with serious mental illness
1. Adult 19-44 years 2. Severe mental disorder 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Perphenazine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
1. Multiple Sclerosis 2. Huntington's Chorea 3. Frontotemporal Dementia 4. Progressive Supranuclear Ophthalmoplegia 5. Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy
Provide patient population that should be included in the study
Fluphenazine decanoate (depot) and enanthate for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacotherapy for anxiety and comorbid alcohol use disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Alcoholism 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Anxiety Disorder 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Schizophrenia 5. Schizophrenic Psychoses 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Schizophrenic Psychoses 7. Aged 65-79 years
Provide patient population that should be included in the study
Alternating current cranial electrotherapy stimulation (CES) for depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Depression 5. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological interventions for preventing post‐traumatic stress disorder (PTSD)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Trauma 6. Aged 65-79 years
Provide patient population that should be included in the study
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Pericyazine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Carbamazepine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Depressed Bipolar I Disorder 4. Middle Aged 45-64 years 5. Electroconvulsive therapy 6. Young Adult 19-24 years 7. Depression 8. General Anesthesia 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Sulpiride versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
General physical health advice for people with serious mental illness
1. Adult 19-44 years 2. Severe mental disorder 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
1. Dementia Due To Alzheimer's Disease
Provide patient population that should be included in the study
Physical health care monitoring for people with serious mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Severe mental disorder 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Respite care for people with dementia and their carers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Caregiver 6. Aged 65-79 years 7. Dementia
Provide patient population that should be included in the study
Perazine for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Chlorpromazine versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Schizophrenic Psychoses 7. Aged 65-79 years
Provide patient population that should be included in the study
Aripiprazole versus other atypical antipsychotics for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute Schizophrenia-like Psychotic Disorder 5. Young Adult 19-24 years 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Neuroleptic-induced hypersalivation 5. Young Adult 19-24 years 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Agomelatine versus other antidepressive agents for major depression
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Depression 6. Aged 65-79 years 7. Major depressive disorder
Provide patient population that should be included in the study
Quetiapine versus other atypical antipsychotics for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Haloperidol versus placebo for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Aged 65-79 years
Provide patient population that should be included in the study
Pimozide for schizophrenia or related psychoses
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Schizophrenic Psychoses 7. Aged 65-79 years
Provide patient population that should be included in the study
Dietary supplements for preventing postnatal depression
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Bipolar Disorder 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Atypical antipsychotics for psychosis in adolescents
1. Schizophrenic Related Disorders 2. Schizophrenia 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for depression
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Depression 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Driving assessment for maintaining mobility and safety in drivers with dementia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Dementia
Provide patient population that should be included in the study
Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia
1. Mixed Dementia 2. Vascular Dementia 3. Dementia Due To Alzheimer's Disease
Provide patient population that should be included in the study
Flow‐regulated versus differential pressure‐regulated shunt valves for adult patients with normal pressure hydrocephalus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Normal Pressure Hydrocephalus 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Rivastigmine for vascular cognitive impairment
1. Vascular Dementia 2. Mixed Dementia 3. Mild Cognitive Impairment
Provide patient population that should be included in the study
Quetiapine versus typical antipsychotic medications for schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenia 6. Schizophrenic Psychoses 7. Aged 65-79 years
Provide patient population that should be included in the study
Intermittent phototherapy versus continuous phototherapy for neonatal jaundice
1. Jaundice 2. Hyperbilirubinemia 3. Infant 1 to 23 mo 4. Birth to 1 mo
Provide patient population that should be included in the study
Volume‐targeted versus pressure‐limited ventilation in neonates
1. Neonate 2. Intermittent Positive Pressure Breathing 3. Birth to 1 mo 4. Intubation 5. Mechanical ventilation
Provide patient population that should be included in the study
Early planned removal of umbilical venous catheters to prevent infection in newborn infants
1. Neonate 2. Birth to 1 mo 3. Umbilical Venous Catheter Placement
Provide patient population that should be included in the study
Cerebral near‐infrared spectroscopy monitoring for prevention of brain injury in very preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo
Provide patient population that should be included in the study
Sildenafil for pulmonary hypertension in neonates
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Pulmonary Hypertension 4. Preterm Infant
Provide patient population that should be included in the study
Fluid supplementation for neonatal unconjugated hyperbilirubinaemia
1. Neonate 2. Neonatal Unconjugated Hyperbilirubinemia 3. Birth to 1 mo